Cardiologist, MD, PhD student in Florence 🇮🇹Interested in #cardiomyopathies #HCM #amyloidosis
Joined December 2019
- Tweets2.4K
- Following513
- Followers742
- Likes4K
Alessia Argiró retweeted
Consistent effect of vurtisiran across different background heart failure therapies in the HELIOS-B trial
jacc.org/doi/10.1016/j.jacc.…
Alessia Argiró retweeted
Important data on NTproBNP and serum TTR level
We've always known about the inverse relationship of these variables at baseline - but the data provided help one understand patients risk. They also provide evidence to the significance of TTR level at baseline and an indirect evidence that the change in that level is important. However, we still cant equate the risk at a certain baseline measure off drug to the same level on drug. Pharmacological manuipulation might not carry the same magnitude of effect. An important future use of TTR, if validated, is to define lack of response to TTR directed therapies.
ahajournals.org/doi/10.1161/…
#CardioTwitter
Alessia Argiró retweeted
After a good 6 years (phew!), our work on pangenomic applications on targeted sequencing is finally out in @GenomeMedicine ➡️ link.springer.com/article/10…
🧬🖥️ 👩🔬
Alessia Argiró retweeted
2026 HRS/PACES scientific statement on the use of antiarrhythmic drugs in understudied clinical scenarios
@DanielPMorin
heartrhythmjournal.com/artic…
Alessia Argiró retweeted
Very good editorial on LBBA versus biventricular pacing in @ESC_Journals
Essential information about ECG patterns and CRT response below!
academic.oup.com/eurheartj/a…
Alessia Argiró retweeted
Ya está disponible en @cardioteca mi selección de lo mejor del congreso ESC en amiloidosis.
Si me he dejado algo importante, os animo a dejarlos en comentarios.
cardioteca.com/blog-amiloido…
Alessia Argiró retweeted
MUSIC-HFpEF trial: Intracoronary gene therapy with AAV1.SERCA2a normalized cardiac filling pressures of HFpEF patients through 12 months, demonstrating target engagement and restoration of calcium handling. Download slides here: clinicaltrialresults.org/wp-…
Alessia Argiró retweeted
Diagnosis of cardiac amyloidosis with a single test-I124 evuzamitide PET/CT: a (-) scan excludes and a (+) scan confirms it. Can image multiple amyloid types and in multiple organs. Grateful to the commitment of patients, investigators, & study committees of the REVEAL trial.
Alessia Argiró retweeted
📣 NEW CONSENSUS DOCUMENT
Just published on #Europace
Workup and management of rhythm disorders in myocarditis and inflammatory cardiomyopathy ⚡️
🔗 doi.org/10.1093/europace/eua…
@EHRAPresident @HFA_President @HRSonline @APHRSOfficial @LAHRSonline1 @GiovanniPeretto
#ESCCongress
Alessia Argiró retweeted
@DorbalaSharmila presented the results of the #REVEAL study - Evuzamitide PET/CT in cardiac amyloidosis
Amazing results of this first ever rigorously conducted multicenter trial of an imaging agent in cardiac amyloidosis
We are so thankful for the commitment of patients and investigators to the conduct of this investigator initiated trial.
Simultaneously published in @JAMA_current
jamanetwork.com/journals/jam…
#cardiotwitter
#ESC2026
#ESCCongress
#ESCCongress2026
#ESCCongressMedIQ
Alessia Argiró retweeted
Even if you never care for patients with cardiac amyloidosis, the CARDIO-TTRansform trial offers lessons in looking beyond soundbite of a clinical trial to understand what the findings really mean for patient care.
voices.nejm.org/doi/full/10.…
@NEJM
Alessia Argiró retweeted
🚨🚨🚨 CARDIO-TTRansform data presented at @escardio #ESCCongress and simultaneously published in @NEJM. The (very surprising!) topline data was released last month – now we get the full data release. Much to break down – it’s all here in the 🧵 below. (1/25) nejm.org/doi/full/10.1056/NE…
Alessia Argiró retweeted
The long road to recognition: a historical review of amyloidosis from early pathology to disease-modifying therapy
Open access for anyone wanting to learn about the history of amyloidosis!
link.springer.com/article/10…
Alessia Argiró retweeted
New must-read for those involved in #amyloidosis management🚨
🆕 2026 Guidelines on hereditary #ATTR 🧬
From pathophysiology to treatment, a great overview 💡
Looking forward to the discussion at @ISA_Amyloidosis in Montevideo 🔍
⏩ doi.org/10.1080/13506129.202…
Alessia Argiró retweeted
nature.com/articles/s44161-0…
Alpha protein kinase 3 gene therapy restores heart function in mouse and human models of cardiomyopathy
Alessia Argiró retweeted
Is Left ventricular hypertrabeculation a distinct entity that requires specific therapeutic management? 🤔
Check our latest study published @CircAHA . 1160 DCM with CMR & 🧬 from 22 🇪🇸/🇳🇱🏥
Amazing work by @NereMA and Noemí Ramos. Congrats! 🎉🎊
See🧵👇🏻
ahajournals.org/doi/10.1161/…
🔥 Is left ventricular hypertrabeculation really a risk marker in dilated cardiomyopathy - or have we been overdiagnosing and overtreating an imaging finding?
🚨 We are thrilled to share our study, now published in @CircAHA !
Alessia Argiró retweeted
Editorial de Peter Schwartz sobre nuestro trabajo acerca del manejo del SQTL en la edad pediátrica en el contexto español.
Menos DAI y más simpatectomía
doi.org/10.1093/eurheartj/eh…
Thrilled to finally be able to share this great paper with you. So happy for the great work of my friends
Paediatric long QT syndrome: clinical outcomes and therapy in the Spanish National Registry academic.oup.com/eurheartj/a…
Alessia Argiró retweeted
It's finally here -- the #Amyloidosis Special Issue from @JACCJournals #JACCCardioOnc! The quality of the manuscripts surpasses anything we could have hoped for. Thank you to all authors & reviewers! Specific highlights below... jacc.org/journal/cardio-onco… jacc.org/doi/pdf/10.1016/S26…
Alessia Argiró retweeted
Systemic light chain and transthyretin amyloidosis—treatment advancements and future directions
thelancet.com/journals/lance…
#ATTRCM #Amyloidosis @TheLancet
Alessia Argiró retweeted
Clinician Lighthouse: This week, Betty Raman and Sanjay Prasad break it down into three steps: recognize the LGE pattern, weigh it against LVEF (not in isolation), then factor in genotype, family history, and arrhythmia burden.
Betty's own words, on this week's Circulation on the Run podcast — a good "Lighthouse lesson," as Jane Wilcox called it.
Read the article: ahajournals.org/doi/10.1161/…
🎧 Listen on Spotify: open.spotify.com/episode/061…
🎧 Listen on Apple: podcasts.apple.com/us/podcas…
@BR_CMR @CircAHA @American_Heart #Cardiology #Circulation #CardiacMRI
ALT Circulation journal cover for Volume 154, Number 5, August 4, 2026, beside a graphic reading 'Clinician Lighthouse: Late Gadolinium Enhancement in Nonischemic Dilated Cardiomyopathy, Featuring: Betty Raman, MD, DPhil,' paired with the Circulation on the Run podcast logo and text reading 'Listen now on Apple & Spotify.